A patient-administered digital tool is efficient, usable and effective at identifying patients who need genetic testing to assess their hereditary risk of cancer.

Jenna Petersen, Andi Hila, Kiley Johnson, Ashley Daley, Colleen Caleshu; Genome Medical

A patient-administered digital tool is efficient, usable and effective at identifying patients who need genetic testing to assess their hereditary risk of cancer.

Jenna Petersen, Andi Hila, Kiley Johnson, Ashley Daley, Colleen Caleshu; Genome Medical

Background

80% of patients with a hereditary risk for cancer are unaware of their risk. Scalable approaches to identifying patients who have a hereditary risk for cancer are needed in order to enable prevention and early detection of cancer. 

RISE Risk Assessment Module: Hereditary Cancer is a patient-administered digital tool that has been clinically validated to identify individuals who may benefit from cancer genetic testing.

Aim

To evaluate the usability and yield of this hereditary cancer risk assessment tool in ob-gyn clinics.

Methods

Retrospective chart review of patients who interacted with the tool in obstetrics and gynecology (ob-gyn) clinics.

Results

Conclusion

There is a clear need for identification of hereditary cancer risk in this setting given number of patients who met criteria and had no prior history of cancer.

These results represent a promising approach to scalable hereditary cancer risk assessment for a variety of care settings across health systems.

Background

80% of patients with a hereditary risk for cancer are unaware of their risk. Scalable approaches to identifying patients who have a hereditary risk for cancer are needed in order to enable prevention and early detection of cancer. 

RISE Risk Assessment Module: Hereditary Cancer is a patient-administered digital tool that has been clinically validated to identify individuals who may benefit from cancer genetic testing.

Aim

To evaluate the usability and yield of this hereditary cancer risk assessment tool in ob-gyn clinics.

Methods

Retrospective chart review of patients who interacted with the tool in obstetrics and gynecology (ob-gyn) clinics.

Results

Conclusion

There is a clear need for identification of hereditary cancer risk in this setting given number of patients who met criteria and had no prior history of cancer.

These results represent a promising approach to scalable hereditary cancer risk assessment for a variety of care settings across health systems.